This article is more than 5 years old. Information may no longer be current.

EyeGate Pharmaceuticals reports higher net loss in third quarter

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

EyeGate Pharmaceuticals reported a $3.377 million net loss in the third quarter, compared with a $1.356 million net loss in the third quarter of 2015, according to a company press release.

A phase 3 confirmatory trial of EGP-437 for the treatment of anterior uveitis, a phase 1b/2a trial for the treatment of post-cataract surgery inflammation and pain, as well as the development of EyeGate OBG, an ocular bandage gel, were partly attributed to the higher net loss, the release said.

Revenue totaled $0.274 million in the third quarter compared with no revenue in the third quarter a year ago.

Research and development expenses increased by $2.041 million from the third quarter of 2015 to $2.449 million. In addition, general and administrative expenses increased by $0.256 million from the third quarter of 2015 to $1.202 million.